Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV <sub>1</sub> in Chronic Obstructive Pulmonary Disease

<b>Rationale:</b> The slope of decline in forced expiratory volume in 1 second (FEV<sub>1</sub>) is commonly used to reflect the rate of disease progression for descriptive studies and therapeutic trials in chronic obstructive pulmonary disease (COPD). The frequency and duration of spirometric testing needed to report the true slope are unknown. <b>Objectives:</b> We sought to define the minimum frequency and follow-up duration needed to accurately describe the annualized rate of FEV<sub>1</sub> change among patients with moderate to very severe COPD. <b>Methods:</b> We performed a <i>post hoc</i> analysis of the annualized rate of FEV<sub>1</sub> change among 4,412 subjects previously enrolled in the 4-year Understanding Potential Long-Term Impacts on Function with Tiotropium-or, UPLIFT-trial of tiotropium versus placebo. Slope estimates were modeled for different iterations of semiannual or annual testing over a variable duration up to 42 months. All models were compared with a reference of semiannual spirometry for 42 months. <b>Results:</b> The overall annual rate of postbronchodilator FEV<sub>1</sub> decline measured semiannually for 42 months (44.6 ml; 95% confidence interval [CI] = 42.5-46.6) did not differ significantly from annual spirometry over the same period (43.7 ml; 95% CI = 41.3-46.1) or semiannual spirometry over the first 2 years (44.3 ml; 95% CI = 41.1-47.5). Agreement was consistent for two follow-up values as far as 24 months apart (43.3 ml; 95% CI = 39.9-46.8). Models that are based on less than two follow-up values or a duration less than 18 months were characterized by relative underestimation of the slope. <b>Conclusions:</b> In a large cohort of patients with moderate to very severe COPD, the annualized rate of change in FEV<sub>1</sub> was accurately represented by a minimum of two annual follow-up measurements over 18 months compared with semiannual testing over 42 months.

Authors

Institutions

Publication Details

Journal
Annals of the American Thoracic Society
Published
2024-08-21
DOI
https://doi.org/10.1513/annalsats.202401-099oc
Citations
6
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
2.51
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV 1 in Chronic Obstructive Pulmonary Disease

Igor Barjaktarević, Holly Wilhalme, Donald P. Tashkin, Jared D. Wilkinson et al.
6 citations
Annals of the American Thoracic Society
Chronic Obstructive Pulmonary Disease (COPD) Research
2.51
article

Duration and Frequency of Spirometry Needed to Accurately Reflect Annualized Change of FEV 1 in Chronic Obstructive Pulmonary Disease

Igor Barjaktarević, Holly Wilhalme, Donald P. Tashkin, Jared D. Wilkinson, Christopher B. Cooper
article en
6 citations

Abstract

<b>Rationale:</b> The slope of decline in forced expiratory volume in 1 second (FEV<sub>1</sub>) is commonly used to reflect the rate of disease progression for descriptive studies and therapeutic trials in chronic obstructive pulmonary disease (COPD). The frequency and duration of spirometric testing needed to report the true slope are unknown. <b>Objectives:</b> We sought to define the minimum frequency and follow-up duration needed to accurately describe the annualized rate of FEV<sub>1</sub> change among patients with moderate to very severe COPD. <b>Methods:</b> We performed a <i>post hoc</i> analysis of the annualized rate of FEV<sub>1</sub> change among 4,412 subjects previously enrolled in the 4-year Understanding Potential Long-Term Impacts on Function with Tiotropium-or, UPLIFT-trial of tiotropium versus placebo. Slope estimates were modeled for different iterations of semiannual or annual testing over a variable duration up to 42 months. All models were compared with a reference of semiannual spirometry for 42 months. <b>Results:</b> The overall annual rate of postbronchodilator FEV<sub>1</sub> decline measured semiannually for 42 months (44.6 ml; 95% confidence interval [CI] = 42.5-46.6) did not differ significantly from annual spirometry over the same period (43.7 ml; 95% CI = 41.3-46.1) or semiannual spirometry over the first 2 years (44.3 ml; 95% CI = 41.1-47.5). Agreement was consistent for two follow-up values as far as 24 months apart (43.3 ml; 95% CI = 39.9-46.8). Models that are based on less than two follow-up values or a duration less than 18 months were characterized by relative underestimation of the slope. <b>Conclusions:</b> In a large cohort of patients with moderate to very severe COPD, the annualized rate of change in FEV<sub>1</sub> was accurately represented by a minimum of two annual follow-up measurements over 18 months compared with semiannual testing over 42 months.

Annals of the American Thoracic SocietyVol. 21(12)
University of California, Los Angeles (US), Inova Fairfax Hospital (US), Olive View-UCLA Medical Center (US), Harbor–UCLA Medical Center (US)
Climate action
Openalex Percentile: Top 10%
Chronic Obstructive Pulmonary Disease (COPD) Research
2.51
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.